 CAMBRIDGE, Mass., Jan. 07, 2021 GLOBE NEWSWIRE -- Constellation Pharmaceuticals, Inc. Nasdaq: CNST today announced the appointment of Brendan Delaney to the newly created position of Chief Commercial Officer, effective January 11, 2021. In this role, Mr. Delaney will be responsible for building and leading the Companys commercial organization and pre-launch preparations in support of CPI-0610, which has the potential to be a disease-modifying therapy for patients living with myelofibrosis. 